Combined effect of doxazosin and pindolol on blood pressure control and lipid concentrations in patients with essential hypertension selected from general practice. Hunter Hypertension Research Group.
Doxazosin, an alpha-adrenergic antagonist with potentially favourable effects on lipid status was evaluated in 25 otherwise healthy general practice patients with mild to moderate hypertension. A mean dose of 5.7 mg produced a significant fall in lying and standing systolic and diastolic blood pressure over an 11 week period as well as an 8% increase in HDL cholesterol and a 7.5% decrease in the total cholesterol/HDL cholesterol ratio. Following this, the doxazosin dose was halved and pindolol, a beta-blocker with intrinsic sympathomimetic activity, was added (mean dose 7.8 mg) to maintain blood pressure control. At the completion of 11 weeks of combined alpha- and beta-blockade, HDL cholesterol and triglyceride levels were found to be unaltered when compared to pretreatment; however there was a small but significant fall in total cholesterol. This study demonstrates that this combination of alpha- and beta-blocking antihypertensive therapy can produce potentially favourable blood lipid changes.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D017292:Doxazosin; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005194:Family Practice; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010869:Pindolol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011224:Prazosin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D008055:Lipids; D010869:Pindolol; D017292:Doxazosin; D011224:Prazosin